Outcomes in COVID-19 FX06 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -10% 1 49 Improvement, Studies, Patients Relative Risk Mortality -10% 1 49 RCTs -10% 1 49 Late -10% 1 49 FX06 for COVID-19 c19early.org November 2025 FavorsFX06 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] death 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Effect extraction pre-specified(most serious outcome) Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] death 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Effect extraction pre-specified(most serious outcome) Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] death 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Effect extraction pre-specified(most serious outcome) Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] death 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Late treatment -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk All studies -10% 1.10 [0.47-2.56] 8/25 7/24 10% higher risk 1 FX06 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.84 Effect extraction pre-specified(most serious outcome) Favors FX06 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Guérin (DB RCT) -10% 1.10 [0.47-2.56] death 8/25 7/24 Ventilated patients Improvement, RR [CI] Treatment Control FX06 COVID-19 outcomes c19early.org November 2025 Favors FX06 Favors control